Efficacy and safety of CD22-specific and CD19/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis

BACKGROUND: CD22 single and CD19/CD22 bispecific targeted chimeric antigen receptor T (CAR-T) cell therapy are promising immunotherapy modalities for the treatment of hematologic malignancies. The aim of this study was to assess the efficacy and safety of CD22 and CD19/CD22 targeted CAR-T cell thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lili, Wang, Luqin, Liu, Qinhua, Wu, Zhonghui, Zhang, Yulong, Xia, Ruixiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837739/
https://www.ncbi.nlm.nih.gov/pubmed/36644638
http://dx.doi.org/10.3389/fonc.2022.954345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837739/
https://www.ncbi.nlm.nih.gov/pubmed/36644638
http://dx.doi.org/10.3389/fonc.2022.954345

Ejemplares similares